| Full text | |
| Author(s): |
de Campos Fraga-Silva, Thais Fernanda
[1, 2]
;
Maruyama, Sandra Regina
[3]
;
Sorgi, Carlos Arterio
[4]
;
de Sousa Russo, Elisa Maria
[5]
;
Morais Fernandes, Ana Paula
[6]
;
de Barros Cardoso, Cristina Ribeiro
[2, 5]
;
Faccioli, Lucia Helena
[2, 5]
;
Dias-Baruffi, Marcelo
[5]
;
Deperon Bonato, Vania Luiza
[1, 2]
Total Authors: 9
|
| Affiliation: | [1] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Biochem & Immunol, Ribeirao Preto, SP - Brazil
[2] Univ Sao Paulo, Ribeirao Preto Med Sch, Basic & Appl Immunol Program, Ribeirao Preto, SP - Brazil
[3] Univ Fed Sao Carlos, Dept Genet & Evolut, Sao Carlos - Brazil
[4] Univ Sao Paulo, Fac Philosophy Sci & Letters Ribeirao Preto, Dept Chem, Ribeirao Preto - Brazil
[5] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal Toxicol & Food Sci Anal, Ribeirao Preto - Brazil
[6] Univ Sao Paulo, Sch Nursing Ribeirao Preto, Dept Gen & Specialized Nursing, Ribeirao Preto - Brazil
Total Affiliations: 6
|
| Document type: | Review article |
| Source: | FRONTIERS IN IMMUNOLOGY; v. 11, JAN 29 2021. |
| Web of Science Citations: | 2 |
| Abstract | |
In the last few months, the coronavirus disease 2019 (COVID-19) pandemic has affected millions of people worldwide and has provoked an exceptional effort from the scientific community to understand the disease. Clinical evidence suggests that severe COVID-19 is associated with both dysregulation of damage tolerance caused by pulmonary immunopathology and high viral load. In this review article, we describe and discuss clinical studies that show advances in the understanding of mild and severe illness and we highlight major points that are critical for improving the comprehension of different clinical outcomes. The understanding of pulmonary immunopathology will contribute to the identification of biomarkers in an attempt to classify mild, moderate, severe and critical COVID-19 illness. The interface of pulmonary immunopathology and the identification of biomarkers are critical for the development of new therapeutic strategies aimed to reduce the systemic and pulmonary hyperinflammation in severe COVID-19. (AU) | |
| FAPESP's process: | 20/05270-0 - Role of human airway epithelial cell death in the inflammation caused by 2019-nCoV and confirmation by transcriptional analysis of infected patients |
| Grantee: | Vânia Luiza Deperon Bonato |
| Support Opportunities: | Regular Research Grants |
| FAPESP's process: | 17/21629-5 - Strategies to study pulmonary inflammation during comorbidities |
| Grantee: | Vânia Luiza Deperon Bonato |
| Support Opportunities: | Research Projects - Thematic Grants |
| FAPESP's process: | 20/05207-6 - Prospective evaluation of lipid mediators production on the immune response against COVID-19: search for biomarkers and new therapeutic targets in the evolution of the disease |
| Grantee: | Lúcia Helena Faccioli |
| Support Opportunities: | Regular Research Grants |